Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of QPI-1002 for prevention of acute kidney injury after cardiac surgery
2015-003113-15Phase 2Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- May 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF) comparing QPI-1002 with Placebo (2 arms). Primary endpoint: Incidence of acute kidney injury through Day 5. Started May 2016; status: completed.
02
Drugs
teprasiran
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2015-003113-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003113-15.